Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 3/20 | 0.46 |
| ▸ | FNTB | P49356 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21327773 | 0.85 | ALDH1A1 (0.47) | CYP2C9TSHRALDH1A1L3MBTL1USP2 | |
| SCHEMBL4957483 | 0.85 | ALDH1A1 (0.47) | CYP2C9TSHRALDH1A1L3MBTL1USP2 | |
| SCHEMBL2549621 | 0.84 | LMNA (0.51) | FNTAFNTB | |
| SCHEMBL14500882 | 0.84 | LMNA (0.51) | FNTAFNTB | |
| SCHEMBL20335057 | 0.84 | CYP2C9 (0.52) | CYP2C9TSHRALDH1A1L3MBTL1USP2 | |
| SCHEMBL20335055 | 0.84 | CYP2C9 (0.52) | CYP2C9TSHRALDH1A1L3MBTL1USP2 | |
| SCHEMBL31307643 | 0.82 | MME (0.46) | CYP2C9ALDH1A1CYP2C19 | |
| SCHEMBL31307607 | 0.82 | MME (0.46) | CYP2C9ALDH1A1CYP2C19 | |
| Phosphoric Acid SCHEMBL11686236 | 0.81 | L3MBTL1 (0.45) | CYP2C9ALDH1A1L3MBTL1USP2FNTA | |
| SCHEMBL14521501 | 0.81 | CYP2C9 (0.55) | CYP2C9TSHRALDH1A1L3MBTL1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442834-B2 | Deprotection method | AJINOMOTO CO., INC. (JP) | 2019-10-15 | — | — | US | disclosed |
| US-20160024143-A1 | DEPROTECTION METHOD | AJINOMOTO CO., INC. (JP) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442834-B2 | Deprotection method | CBR1, AOX1, AOC2 | CYP2C9 223/4885TSHR 819/4885ALDH1A1 9/4885 |
| US-20160024143-A1 | DEPROTECTION METHOD | CBR1, AOX1, AOC2 | CYP2C9 223/4885TSHR 819/4885ALDH1A1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.